Cidara Therapeutics will stop work on its antifungal CD101 in women with acute VVC, after the topical candidate failed a mid-stage trial.

Pfizer said the FDA has given its experimental leukemia med inotuzumab ozogamicin a priority review as it gets to work on assessing the medication for approval.

Sarepta has struck a $125 million deal to sell a voucher it got with last year’s controversial FDA approval of its new Duchenne drug to Gilead, which will give…

The biotech's CEO says the clinical trial is the first to show that it is possible to usher large-molecule drugs across the blood-brain barrier.

Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the London Stock Exchange as it looks to put the…

Takeda and TiGenix have presented 52-week data on their stem cells in Crohn’s disease patients with treatment-refractory complex perianal fistulas.

Gilead has sold a phase 2-ready addiction candidate to Amygdala Neurosciences.

uniQure plans to start a three-pronged clinical trial program next year as key assets from its in-house pipeline and Bristol-Myers Squibb collaboration advance…

Prima Biomed has pushed the accelerator on its in-house drug development program, pressing ahead with two trials of its immuno-oncology drug IMP321 in breast…

R&D